Current Edition

Incoming wave of biosimilars in oncology Special Session at ESMO 2017

Saturday, 9 September, 14:45 to 16:15, Granada Auditorium, IFEMA

Biosimilars are a much-needed and timely opportunity for physicians, patients and healthcare systems. Be the first to hear the latest developments in this exciting field.
The European Medicines Agency will discuss its plan for healthcare professionals, and a clinician will talk about how to build confidence to prescribe biosimilars. The crucial role of specialist nurses will be highlighted, and a patient will provide a perspective on what has been learned and what can be improved. The potential for biosimilars to improve the financial sustainability of healthcare systems will also be discussed. Read the ESMO position paper on biosimilars here. (2)
Get up to speed on how regulators, healthcare professionals and patients are preparing for the increasing role of biosimilars in the treatment of cancer by coming to the session.
A survey on biosimilars will be available to track the understanding of biosimilars, as well as the current and future needs on this topic.
1 The Special Session ‘The incoming wave of biosimilars in oncology’ takes place on Saturday, 9 September 2017, 14:45 to 16:15 (CEST) in Granada Auditorium.
2 Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersESMO Open. 2016;1:e000142. doi:10.1136/ esmoopen-2016-000142
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.